| Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202) M Coleman, D Belada, RO Casasnovas, R Gressin, HP Lee, A Mehta, ... Leukemia & Lymphoma 62 (2), 368-376, 2021 | 25 | 2021 |
| Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory marginal zone lymphoma (CITADEL-204) TJ Phillips, P Corradini, R Gurion, C Patti, M Tani, A Avigdor, W Jurczak, ... Blood 136, 27-28, 2020 | 15 | 2020 |
| Parsaclisib in Japanese patients with relapsed or refractory B‐cell lymphoma (CITADEL‐111): A phase Ib study N Fukuhara, Y Suehiro, H Kato, S Kusumoto, C Coronado, E Rappold, ... Cancer Science 113 (5), 1702-1711, 2022 | 7 | 2022 |
| Incorporating covariates information in adaptive clinical trials for precision medicine W Zhao, W Ma, F Wang, F Hu Pharmaceutical Statistics 21 (1), 176-195, 2022 | 7 | 2022 |
| Efficacy and safety of parsaclisib in patients with relapsed or refractory marginal zone lymphoma: primary analysis from a phase 2 study (CITADEL-204) T Phillips, A Avigdor, R Gurion, C Patti, P Corradini, M Tani, A Mehta, ... Blood 138, 44, 2021 | 6 | 2021 |
| Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL)(CITADEL-202). M Coleman, D Belada, RO Casasnovas, R Gressin, HP Lee, A Mehta, ... Journal of Clinical Oncology 37 (15_suppl), e19038-e19038, 2019 | 4 | 2019 |
| Takeaim lymphoma: an open-label, dose escalation and expansion trial of emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed or refractory hematologic … C Grommes, H Tun, AC Rosenthal, MA Lunning, R Ramchandren, ... Blood 142, 4497, 2023 | 3 | 2023 |
| Molecular characterization of clinical response in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome patients treated with single agent emavusertib KH Metzeler, ES Winer, U Platzbecker, A Verma, DJ DeAngelo, ... Blood 140 (Supplement 1), 9048-9049, 2022 | 2 | 2022 |
| Optimizing single-mode collection from pointlike sources of single photons with adaptive optics AD Hill, D Hervas, J Nash, M Graham, A Burgers, U Paudel, D Steel, ... Optics Express 25 (16), 18629-18642, 2017 | 2 | 2017 |
| A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204) TJ Phillips, A Avigdor, R Gurion, C Patti, P Corradini, M Tani, A Mehta, ... Blood Advances 8 (4), 867-877, 2024 | 1 | 2024 |
| Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Acute Myeloid Leukemia Patients with FLT3 Mutation ES Winer, A Verma, S Groepper, KSS Götze, Y Abaza, C Schliemann, ... Blood 142, 2924, 2023 | 1 | 2023 |
| PRELIMINARY SAFETY AND EFFICACY DATA ON TWO PATIENTS WITH RELAPSED/REFRACTORY CNS LYMPHOMA TREATED WITH EMAVUSERTIB (CA-4948) AND IBRUTINIB COMBINATION: A SUBSET ANALYSIS OF … AR Madiha Iqbal, Han Tun, Erel Joffe, Christian Grommes, Grzegorz Nowakowski ... neuro-oncology 24 (Supplement_7), vii68–vii69, 2022 | 1* | 2022 |
| P1102: A PHASE 1 STUDY OF PARSACLISIB IN COMBINATION WITH RITUXIMAB, BENDAMUSTINE+ RITUXIMAB, OR IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B-CELL LYMPHOMA (CITADEL-112 … JM Sancho, A Lopez-Guillermo, P Abrisqueta, A Kumar, R Cordoba, ... HemaSphere 6, 992-993, 2022 | 1 | 2022 |
| 688 Transcriptome analyses in patients with myeloid malignances treated with the IRAK4 inhibitor emavusertib KH Metzeler, U Platzbecker, ES Winer, A Verma, DJ DeAngelo, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| A Phase 1 Study of Parsaclisib in Combination with Investigator Choice of Rituximab, Bendamustine+ Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma … JM Sancho, A Lopez-Guillermo, P Abrisqueta, A Kumar, R Cordoba, ... 2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2022 | | 2022 |
| PHASE 2 STUDY OF PARSACLISIB (INCB050465) FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)(CITADEL‐202) D Belada, K Fay, R Casasnovas, R Gressin, H Lee, A Mehta, J Munoz, ... Hematological Oncology 37, 326-327, 2019 | | 2019 |
